Open AccessEffect of DNA damage response mutations on prostate cancer prognosis: a systematic review
Author(s) -
Stephanie L. Swift,
Shona Lang,
Heath White,
Kate Misso,
Jos Kleijnen,
Ruben G.W. Quek
Publication year - 2019
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2019-0298
Subject(s) - medicine , fanca , prostate cancer , palb2 , chek2 , oncology , dna damage repair , mlh1 , dna damage , cancer research , dna repair , cancer , mutation , germline mutation , gene , dna mismatch repair , genetics , fanconi anemia , dna , biology , colorectal cancer
The prognosis of men with prostate cancer (PC) with mutations in DNA damage response ( DDR) genes undergoing different treatments is unclear. This systematic review compared clinical outcomes in PC patients with DDR mutations ( DDR + ) versus no mutations ( DDR - ). 14 resources plus gray literature were searched for studies in PC and subgroups (castration-resistant PC, metastatic PC and metastatic castration-resistant PC) by DDR gene ( ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) mutation status. From 11,648 records, 26 studies were included. For mCRPC, six studies reported comparative efficacy for key outcomes. Improvements in several clinical outcomes were observed for DDR + (vs DDR - ) after PARP inhibitor therapy or immunotherapy. DDR + PC patients may have improved outcomes depending on the treatment they undergo.